Table 3: Pre- and post-treatment characteristics of the 485 subjects who developed biochemical (Phoenix) failure before clinical failure according to the most predictive post-biochemical failure risk category (BFRC) stratification scheme.

Post-biochemical failure risk category
LowIntermediateHigh
( )( )( )

Gleason score
 2–6117 (47%)36 (30%)23 (19%)
 7105 (43%)53 (44%)54 (45%)
 8–1024 (10%)31 (26%)42 (35%)

T stage
 T2b73 (30%)23 (19%)16 (13%)
 T2c87 (35%)33 (28%)36 (30%)
 T3,486 (35%)64 (53%)67 (56%)

PSA ( g/L)
 <1045 (18%)24 (20%)20 (17%)
 ≥10 and <20102 (41%)38 (32%)24 (20%)
 ≥2099 (40%)58 (48%)75 (63%)

Risk group*
 Intermediate45 (18%)10 (8%)4 (3%)
 High201 (82%)110 (92%)115 (97%)

Primary treatment
 0 months AST107 (44%)45 (38%)40 (34%)
 3 months AST75 (30%)35 (29%)45 (38%)
 6 months AST64 (26%)40 (33%)34 (28%)

Age at BF (years)
 Median (range)74 (54–89)69 (54–88)69 (44–81)

PSADT (months)
 Median (IQR)13.2 (9.4–19.8)5.3 (4.3–6.4)3.0 (1.9–3.8)

TTBF (years)
 Median (IQR)4.6 (3.4–7.3)2.2 (1.5–2.7)0.8 (0.5–1.4)

STI
 No STI121 (49%)13 (11%)8 (7%)
 STI without distant  progression89 (36%)61 (51%)47 (39%)
 STI with distant
 progression
36 (15%)46 (38%)64 (54%)

: number of subjects; PSA: prostate-specific antigen; AST: androgen suppression therapy; PSADT: PSA doubling time; TTBF: time from biochemical (Phoenix) failure; STI: secondary therapeutic intervention; IQR: interquartile range.
*D’Amico et al. risk classification.